Literature DB >> 28501527

Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction.

Boback Ziaeian1, Paul A Heidenreich2, Haolin Xu3, Adam D DeVore4, Roland A Matsouaka5, Adrian F Hernandez4, Deepak L Bhatt6, Clyde W Yancy7, Gregg C Fonarow8.   

Abstract

OBJECTIVES: This study analyzed HFpEF patient characteristics and clinical outcomes according to race/ethnicity and adjusted for patient and hospital characteristics along with socioeconomic status (SES).
BACKGROUND: The proportion of hospitalizations for heart failure with preserved ejection fraction (HFpEF) has increased over the last decade. Whether the short- and long-term outcomes differ between racial/ethnic groups is not well described.
METHODS: The Get With The Guidelines-Heart Failure registry was linked to Medicare administrative data to identify hospitalized patients with HFpEF ≥65 years of age with left ventricular ejection fraction ≥50% between 2006 and 2014. Cox proportional hazards models were used to report hazard ratios (HRs) for 30-day and 1-year readmission and mortality rates with sequential adjustments for patient characteristics, hospital characteristics, and SES.
RESULTS: The final cohort included 53,065 patients with HFpEF. Overall 30-day mortality was 5.87%; at 1 year, it was 33.1%. The 30-day all-cause readmission rate was 22.2%, and it was 67.0% at 1 year. After adjusting for patient characteristics, hospital characteristics, and SES, 30-day mortality was lower for black patients (HR: 0.84; 95% confidence interval [CI]: 0.71 to 0.98; p = 0.031) and Hispanic patients (HR: 0.78; 95% CI: 0.64 to 0.96; p = 0.017) compared with white patients. One-year mortality was lower for black patients (HR: 0.93; 95% CI: 0.87 to 0.99; p = 0.031), Hispanic patients (HR: 0.83; 95% CI: 0.75 to 0.91; p < 0.001), and Asian patients (HR: 0.76; 95% CI: 0.66 to 0.88; p < 0.001) compared with white patients. Black patients had a higher risk of readmission at 30 days (HR: 1.09; 95% CI: 1.02 to 1.16; p = 0.012) and 1 year (HR: 1.14; 95% CI: 1.09 to 1.20; p < 0.001) compared with white patients.
CONCLUSIONS: Black, Hispanic, and Asian patients had a lower mortality risk after a hospitalization for HFpEF compared with white patients; black patients had higher readmission rates. These differences in mortality and readmission risk according to race/ethnicity persisted after adjusting for patient characteristics, SES, and hospital factors.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diastolic heart failure; disparities; ethnicity; heart failure with preserved ejection fraction; hospitalization; mortality; race

Mesh:

Year:  2017        PMID: 28501527      PMCID: PMC5524150          DOI: 10.1016/j.jchf.2017.02.012

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.544


  24 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

Review 2.  Most important articles on cardiovascular disease among racial and ethnic minorities.

Authors:  Purav Mody; Aakriti Gupta; Behnood Bikdeli; Julianna F Lampropulos; Kumar Dharmarajan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-07-01

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 4.  Epidemiology and clinical course of heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Erwan Donal; Elisabeth Kraigher-Krainer; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

5.  A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010.

Authors:  Yariv Gerber; Susan A Weston; Margaret M Redfield; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Jill M Killian; Véronique L Roger
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

6.  Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study.

Authors:  Amy J H Kind; Steve Jencks; Jane Brock; Menggang Yu; Christie Bartels; William Ehlenbach; Caprice Greenberg; Maureen Smith
Journal:  Ann Intern Med       Date:  2014-12-02       Impact factor: 25.391

7.  Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma.

Authors:  Taslima Bhuiyan; Mathew S Maurer
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-10

8.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Authors:  Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2014-07-22       Impact factor: 4.749

9.  Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study.

Authors:  Deepak K Gupta; Amil M Shah; Davide Castagno; Madoka Takeuchi; Laura R Loehr; Ervin R Fox; Kenneth R Butler; Thomas H Mosley; Dalane W Kitzman; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2013-04       Impact factor: 12.035

10.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

View more
  16 in total

1.  Characteristics and in-hospital outcomes of hospitalisations with heart failure with reduced or preserved ejection fraction undergoing percutaneous coronary intervention.

Authors:  Rajkumar Doshi; Krunalkumar Patel; Neelesh Gupta; Rajeev Gupta; Perwaiz Meraj
Journal:  Ir J Med Sci       Date:  2018-10-16       Impact factor: 1.568

2.  Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get With The Guidelines-Heart Failure (GWTG-HF) Registry.

Authors:  Tiffany M Powell-Wiley; Julius Ngwa; Selomie Kebede; Di Lu; Phillip J Schulte; Deepak L Bhatt; Clyde Yancy; Gregg C Fonarow; Michelle A Albert
Journal:  JACC Heart Fail       Date:  2018-02-07       Impact factor: 12.035

3.  Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance.

Authors:  Patricia P Chang; Lisa M Wruck; Eyal Shahar; Joseph S Rossi; Laura R Loehr; Stuart D Russell; Sunil K Agarwal; Suma H Konety; Carlos J Rodriguez; Wayne D Rosamond
Journal:  Circulation       Date:  2018-03-08       Impact factor: 29.690

4.  Performance of the Meta-Analysis Global Group in Chronic Heart Failure Score in Black Patients Compared With Whites.

Authors:  Ryhm Radjef; Edward L Peterson; Alexander Michaels; Bin Liu; Hongsheng Gui; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-07-03

5.  Racial/Ethnic Differences in 30-Day Mortality for Heart Failure and Pneumonia in the Veterans Health Administration Using Claims-based, Clinical, and Social Risk-adjustment Variables.

Authors:  Gabriella C Silva; Lan Jiang; Roee Gutman; Wen-Chih Wu; Vincent Mor; Michael J Fine; Nancy R Kressin; Amal N Trivedi
Journal:  Med Care       Date:  2021-12-01       Impact factor: 2.983

6.  Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10.

Authors:  Peter H Langsjoen; Jens O Langsjoen; Alena M Langsjoen; Franklin Rosenfeldt
Journal:  Perm J       Date:  2019-08-26

7.  Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction.

Authors:  Boback Ziaeian; Paul A Heidenreich; Haolin Xu; Adam D DeVore; Roland A Matsouaka; Adrian F Hernandez; Deepak L Bhatt; Clyde W Yancy; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2018-04-11       Impact factor: 12.035

8.  Readmissions Following a Hospitalization for Cardiovascular Events in Dialysis Patients: A Retrospective Cohort Study.

Authors:  James B Wetmore; Julia T Molony; Jiannong Liu; Yi Peng; Charles A Herzog; Allan J Collins; David T Gilbertson
Journal:  J Am Heart Assoc       Date:  2018-02-13       Impact factor: 5.501

9.  The tip of the iceberg: finding patients with heart failure with preserved ejection fraction in primary care. An observational study.

Authors:  Christi Deaton; Duncan Edwards; Alexandra Malyon; M Justin S Zaman
Journal:  BJGP Open       Date:  2018-09-19

Review 10.  Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Shane Nanayakkara; Hitesh C Patel; David M Kaye
Journal:  Clin Med Insights Cardiol       Date:  2018-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.